Please check your internet connection and try again.
```markdown
# Mylatat
## Overview
Mylatat is a topical formulation containing lidocaine and prilocaine, which are local anesthetics. It works by reversibly blocking nerve impulse conduction, leading to local anesthesia.
## Primary Indications
* Topical anesthesia for intact skin prior to needle insertion (e.g., venipuncture, arterial puncture).
* Topical anesthesia for genital mucosas prior to superficial surgical procedures.
## Adult Dosing
* **Intact Skin:** Apply a thick layer to the intended area, cover with an occlusive dressing. Leave on for at least 60 minutes. Maximum application area is 20 cm² (e.g., 4 cm x 5 cm). The maximum amount to apply is 1 gram per 10 cm².
* **Genital Mucosa:** Apply a thin layer to the genital mucosa. Leave on for 5 to 10 minutes. Do not use on genital mucosa prior to superficial surgical procedures if adequate local anesthesia cannot be achieved with this amount and duration of application.
## Pediatric Dosing
Dosing in pediatric patients varies significantly based on age, weight, and the area of application. Consult specific pediatric guidelines or product labeling. Due to potential for increased systemic absorption and risk of methemoglobinemia, caution is warranted.
* **Infants < 3 months:** Generally not recommended due to immature metabolic pathways and increased risk of methemoglobinemia.
* **Infants 3-12 months:** Maximum application area and duration are restricted. Consult product labeling for specific guidance.
* **Children > 12 months:** Dosing is based on weight and surface area. Do not exceed recommended doses.
## Dose Adjustments
* **Renal Impairment:** No specific dose adjustment is usually required when used topically as systemic absorption is typically low. However, caution may be warranted in severe renal impairment.
* **Hepatic Impairment:** No specific dose adjustment is usually required when used topically. However, caution may be warranted in severe hepatic impairment.
## Contraindications
* Known hypersensitivity to lidocaine, prilocaine, or any other component of the formulation.
* Avoid application to broken or irritated skin, except for genital mucosas as indicated.
* Avoid use in infants under 3 months of age, particularly premature infants.
## Adverse Effects
* **Common:** Skin reactions at the application site (erythema, edema, paleness, burning, itching).
* **Less Common/Serious:** Allergic reactions, methemoglobinemia (especially in infants and with prolonged or extensive application), systemic toxicity (CNS excitation or depression, cardiovascular effects) if significant systemic absorption occurs.
## Key Drug Interactions
* **Methemoglobinemia-inducing agents:** Increased risk of methemoglobinemia when used concurrently with other agents known to induce methemoglobinemia (e.g., sulfonamides, dapsone, nitrofurantoin, phenobarbital).
* **Class Ib antiarrhythmics (e.g., tocainide, mexiletine):** Additive toxicity if significant systemic absorption occurs.
## Monitoring
* Monitor for signs of methemoglobinemia (cyanosis, headache, dizziness, shortness of breath) especially in infants and with extensive application.
* Monitor for signs of systemic local anesthetic toxicity.
* Assess the skin at the application site for adverse reactions.
## Clinical Pearls
* Ensure adequate contact time for effective anesthesia.
* Occlusive dressing is crucial for achieving adequate anesthetic depth on intact skin.
* The risk of methemoglobinemia is dose-dependent and is higher in infants and with prolonged application.
* Avoid application to larger areas than recommended to minimize systemic absorption.
* Wipe off any excess product that may spread to other areas.
***
**Disclaimer:** This information is intended for clinical decision support and does not replace comprehensive drug information resources or clinical judgment. Always consult the most current prescribing information and relevant guidelines before making therapeutic decisions.
```
